CombiGene enters into a license agreement with Spark for the epilepsy project CG01

CombiGene AB (publ) (“CombiGene”, “the Company”) today announces that the Company has entered into a license agreement with Spark Therapeutics (“Spark”) to certain intellectual property developed or used by Spark in connection with the Prior License Agreement for CGO1. Through the license agreement, Spark is eligible to receive a low single digit percentage in royalties on future net sales of Licensed Products. The license agreement assures that CombiGene can use data and inventions and secures critical rights which will facilitate CombiGene’s efforts in finding a new partner for the epilepsy project. According to the agreement, CombiGene will not make any up-front or milestone payments for the license.

The Company and Spark previously collaborated to develop CG01, a gene therapy that express the human neuropeptide Y (NPY) and its receptor Y2 (NPY2R). The Company regained global rights to CGO1 in January 2024 following the termination period of the collaboration and license agreement between the two companies.

Spark will share data from past and current ongoing studies at the latest by early Q4-2024. Through the license agreement, CombiGene will receive the data from these important studies.

We are very pleased to have signed a license agreement with Spark as it enhances our opportunities to find a new suitable partner for the epilepsy project. We can now present new data to potential partners and leverage new findings made by Spark during the continued development of CG01. I want to emphasize that we do not yet have an agreement with a new partner, but we remain optimistic about the future of the CG01 project,” says CombiGene’s CEO Peter Ekolind.

About the epilepsy project CG01
CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.